Intra-articular Injections of Hylan G-F 20 for Pain in Patients with Idiopathic Knee Osteoarthritis .
Three once-weekly intra-articular injections of Hylan G-F 20 significantly improve pain relief compared with placebo in patients with chronic idiopathic knee osteoarthritis: a single-centre, evaluator-blinded and patient-blinded, randomized controlled tri
Drugs Context. 2024 01-Apr;():. 10.7573/dic.2023-11-3Thirty patients with chronic idiopathic knee osteoarthritis (Larsen grade II or III) were randomized to receive three once-weekly intra-articular injections of either Hylan G-F 20 (n=15) or placebo (n=15). The primary outcome was pain relief as assessed by visual analogue scale (VAS) scores at weeks 12 and 26. Secondary outcomes included patient activity level, overall clinical condition, and adverse events. Follow-up occurred at multiple intervals up to 26 weeks. Overall, the study revealed that Hylan G-F 20 significantly improved patient-assessed and evaluator-assessed outcomes (p<0.0001), except for night pain and inactivity stiffness, with no significant safety concerns. These findings suggest that Hylan G-F 20 provides effective and sustained pain relief in this population.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics